Focused ultrasound for the treatment of bone metastases: effectiveness and feasibility

• Published in: Journal of therapeutic ultrasound Vol. 6; no. 1; p. 8
• Main Authors: Bertrand, Anne-Sophie, Iannessi, Antoine, Natale, Romain, Beaumont, Hubert, Patriti, Sebastien, Xiong-Ying, Jiang, Baudin, Guillaume, Thyss, Antoine
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 30-11-2018; BioMed Central
• Subjects: Bone cancer; Cancer metastasis; Cancer therapies; Feasibility studies; Health aspects; Lesions; Magnetic resonance; Magnetic resonance imaging; Medical research; Metastasis; Morphine; NMR; Nuclear magnetic resonance; Pain; Patients; Radiation therapy; Radiotherapy; Rank tests; Surgery; Tumors; Ultrasonic imaging; Ultrasound imaging; Pain; Bone neoplasms; Radiotherapy; High-intensity focused ultrasound; Cancer
• ISSN: 2050-5736; 2050-5736
• DOI: 10.1186/s40349-018-0117-3

To evaluate the effectiveness and feasibility of high-intensity focused ultrasound (HIFU) for the treatment of bone metastases.
A single-center prospective study was made involving 17 consecutive patients with symptomatic bone metastases. Patients were treated by Focused Ultrasound (FUs) performed with magnetic resonance (MR) guidance. Surgical treatment or radiotherapy treatment was not indicated for patients who underwent FUs. Lesions were located in the appendicular and axial skeleton and consisted of secondary symptomatic lesions. The clinical course of pain was evaluated using the Visual Analog Scale (VAS) before treatment, at 1 week, and at 1 month after treatment and the Oral Morphine Equivalent Daily Dose (OMEDD) was also recorded. We used Wilcoxon signed rank test to assess change in patient pain (R CRAN software V 3.1.1).
We observed a significant decrease in the pain felt by patients between pre- procedure and 1 week post-procedure (
 = 2.9.10-4), and pre-procedure and 1 month post-procedure (
 = 3.10-4). The proportion of responders according to the International Bone Metastases Consensus Working Party was: Partial Response 50% (8/16) and Complete Response 37.5% (6/16).
HIFU under MR-guidance seems to be an effective and safe procedure in the treatment of symptomatic bone lesions for patients suffering from metastatic disease. A significant decrease of patient pain was observed.
NCT01091883. Registered 24 March 2010. Level of evidence: Level 3.